Companies House · 04513292

CIPLA (EU) LIMITED

UK registered company, private limited company, incorporated 16 Aug 2002.

Active
36
Public contracts
0
Spend payments
Total spend

CIPLA (EU) LIMITED is a UK company registered at Companies House under number 04513292. This page links its registry record to its activity in UK public procurement — the contracts it has been awarded and the transparency-spend payments recorded against it.

Companies House record

Company number
04513292
Status
Active
Company type
Private Limited Company
Incorporated
16 Aug 2002
Country of origin
United Kingdom
Registered office
DIXCART HOUSE ADDLESTONE ROAD, ADDLESTONE, SURREY, KT15 2LE
Nature of business (SIC)
46460 - Wholesale of pharmaceutical goods; 82990 - Other business support service activities n.e.c.
Accounts category
FULL
View source on data.gov.uk

Public sector contracts

Contract awards linked to CIPLA (EU) LIMITED.

ProcurementBuyerAwardedValue
NHS national Generic Pharmaceuticals Transition 2021_2The NHS Commissioning Board (operating under the name of NHS England)
NHS National Proprietary Category Tender - 1 May 2024NHS England
NHS National Generic Pharmaceuticals Wave 13The NHS Commissioning Board (operating under the name of NHS England)
NHS National Generic Pharmaceuticals Wave 13The NHS Commissioning Board (operating under the name of NHS England)
NHS National Pharmaceuticals — Fulvestrant, Darunavir and ImatinibThe NHS Commissioning Board (operating under the name of NHS England)
Proprietary DrugsVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
NHS national Generic Pharmaceuticals Transition 2021_2The NHS Commissioning Board (operating under the name of NHS England)
NHS national Generic Pharmaceuticals Transition 2021_2The NHS Commissioning Board (operating under the name of NHS England)
NHS national Generic Pharmaceuticals Transition 2021_2The NHS Commissioning Board (operating under the name of NHS England)
NHS national Generic Pharmaceuticals Transition 2021_2The NHS Commissioning Board (operating under the name of NHS England)
Cardiovascular & Respiratory MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
Cardiovascular & Respiratory MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
Cardiovascular & Respiratory MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
NP39724 Generic and Biosimilar Cancer MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Proprietary DrugseTenderwales
NHS National Pharmaceuticals Transition 2021_3The NHS Commissioning Board (operating under the name of NHS England)
NHS National Pharmaceuticals Transition 2021_3The NHS Commissioning Board (operating under the name of NHS England)
NHS National Pharmaceuticals Transition 2021_3The NHS Commissioning Board (operating under the name of NHS England)
NHS National Generic Pharmaceuticals Interim 2 2020The NHS Commissioning Board (operating under the name of NHS England)
NHS National Generic Pharmaceuticals Interim 2 2020The NHS Commissioning Board (operating under the name of NHS England)
NHS national Generic Pharmaceuticals Transition 2021_2The NHS Commissioning Board (operating under the name of NHS England)
NHS National Generics Pharmaceuticals - Supply Chain ResilienceNHS England30 Apr 2026£35m
NHS National Branded Interim - 1 June 2026NHS England9 Apr 2026£529.1m
NHS Generic Pharmaceuticals - Wave 15cNHS England13 Jan 2026£403.7m
NHS Generic Pharmaceuticals - Wave 15cNHS England13 Jan 2026£17.7m
NHS National Framework for Generics HousekeepingNHS England10 Nov 2025£21.6m
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024NHS England4 Apr 2024£1bn
NHS National Generic Pharmaceuticals Wave 13ATAMIS LTD30 Nov 2021£469.7m
NHS National Generic Pharmaceuticals Wave 13ATAMIS LTD30 Nov 2021£469.7m
NHS National Generic Pharmaceuticals Wave 13ATAMIS LTD30 Nov 2021£469.7m
NHS National Pharmaceuticals Transition 2021_3NHS England21 Oct 2021£26m
NHS National Generic Pharmaceuticals - Transition 2021_2NHS England31 Mar 2021£2.8m
NHS National Pharmaceuticals - Fulvestrant, Darunavir and ImatinibNHS England4 Jan 2021£17.3m
NHS National Generic Pharmaceuticals Interim 2NHS England21 Dec 2020£12.3m
NHS National Generic Pharmaceuticals Interim 2NHS England21 Dec 2020£12.3m
NHS Framework Agreement for Branded Medicines - NationalNHS England30 Apr 2019£1.4bn

Supplier identities

How this company appears as a supplier across the data.

FAQs about CIPLA (EU) LIMITED

Is CIPLA (EU) LIMITED an active company?

CIPLA (EU) LIMITED (company number 04513292) is recorded as "Active", incorporated on 16 Aug 2002.

What does CIPLA (EU) LIMITED do?

Its Companies House nature-of-business (SIC) is: 46460 - Wholesale of pharmaceutical goods; 82990 - Other business support service activities n.e.c..

Has CIPLA (EU) LIMITED won UK public-sector contracts?

Yes — 36 public-sector contract awards are linked to this company in our data.

Where is CIPLA (EU) LIMITED based?

Its registered office is DIXCART HOUSE ADDLESTONE ROAD, ADDLESTONE, SURREY, KT15 2LE.

Understand any company's public-sector footprint

Enable links Companies House to live procurement and spend data — see contracts, buyers and payments for any UK supplier.

Get in touch with Enable